High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

Homer C. Adams, Janssen Research & Development
Frederik Stevenaert, Janssen Research & Development
Jakub Krejcik, University of Southern Denmark
Koen Van der Borght, Janssen Research & Development
Tina Smets, Janssen Research & Development
Jaime Bald, Janssen Research & Development
Yann Abraham, Janssen Research & Development
Hugo Ceulemans, Janssen Research & Development
Chiristopher Chiu, Janssen Research & Development
Greet Vanhoof, Janssen Research & Development

Only first 10 authors above; see publication for full author list.

Journal Title: Cytometry Part A
Volume: Volume 95A, Number 3
Publisher: Wiley: 12 months | 2019-03-01, Pages 279-289
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1002/cyto.a.23693
Permanent URL: https://pid.emory.edu/ark:/25593/tvf25

Final published version: http://dx.doi.org/10.1002/cyto.a.23693

Copyright information:
© 2018 The Authors. Cytometry Part A published by Wiley Periodicals, Inc. on behalf of International Society for Advancement of Cytometry. This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed January 22, 2020 4:37 PM EST
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

Homer C. Adams III,1* Frederik Stevenaert,2 Jakub Krejcik,3,4 Koen Van der Borght,2 Tina Smets,2 Jaime Bald,1 Yann Abraham,2 Hugo Ceulemans,2 Christopher Chiu,1 Greet Vanhoof,2 Saad Z. Usmani,5 Torben Plesner,4 Sagar Lonial,6 Inger Nijhof,3 Henk M. Lokhorst,3 Tuna Mutis,3 Niels W.C.J. van de Donk,3 Amy Kate Sasser,7 Tineke Casneuf2

Abstract

Daratumumab is a CD38-targeted human monoclonal antibody with direct anti-myeloma cell mechanisms of action. Flow cytometry in relapsed and/or refractory multiple myeloma (RRMM) patients treated with daratumumab revealed cytotoxic T-cell expansion and reduction of immune-suppressive populations, suggesting immune modulation as an additional mechanism of action. Here, we performed an in-depth analysis of the effects of daratumumab on immune-cell subpopulations using high-dimensional mass cytometry. Whole-blood and bone-marrow baseline and on-treatment samples from RRMM patients who participated in daratumumab monotherapy studies (SIRIUS and GEN501) were evaluated with high-throughput immunophenotyping. In daratumumab-treated patients, the intensity of CD38 marker expression decreased on many immune cells in SIRIUS whole-blood samples. Natural killer (NK) cells were depleted with daratumumab, with remaining NK cells showing increased CD69 and CD127, decreased CD45RA, and trends for increased CD25, CD27, and CD137 and decreased granzyme B. Immune-suppressive population depletion paralleled previous findings, and a newly observed reduction in CD38+ basophils was seen in patients who received monotherapy. After 2 months of daratumumab, the T-cell population in whole-blood samples from responders shifted to a CD8 prevalence with higher granzyme B positivity (P = 0.017), suggesting increased killing capacity and supporting monotherapy-induced CD8+ T-cell activation. High-throughput cytometry immune profiling confirms and builds upon previous flow cytometry data, including comparable CD38 marker intensity on plasma cells, NK cells, monocytes, and B/T cells. Interestingly, a shift toward cytolytic granzyme B+ T cells was also observed and supports adaptive responses in patients that may contribute to depth of response. © 2018 The Authors. Cytometry Part A published by Wiley Periodicals, Inc. on behalf of International Society for Advancement of Cytometry.

Key terms

CyTOF; immune profiling; cytometry by time of flight

INTRODUCTION

Daratumumab is a human monoclonal antibody that targets CD38, a type II transmembrane glycoprotein that is highly and ubiquitously expressed on myeloma cells (1–4). In clinical studies, daratumumab has shown impressive anti-myeloma activity in patients with relapsed and/or refractory multiple myeloma (RRMM), both when administered as monotherapy and when given in combination with standard-of-care agents (5–10). In Part 2 of the GEN501 monotherapy study, at a median
follow-up of 10.2 months, patients in the 16 mg/kg daratumumab cohort had an overall clinical response rate of 36%. The median duration of response was not reached, and progression-free survival was 5.6 months (5). Additionally, in the phase 2 SIRIUS monotherapy study, patients who received 16 mg/kg daratumumab had an overall response rate of 29.2% and median progression-free survival of 3.7 months at a median follow-up of 9.3 months (6). These studies led to the first approval of daratumumab by the US Food and Drug Administration for patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or who are double refractory to a proteasome inhibitor and an immunomodulatory agent (11).

Daratumumab induces deep and durable clinical responses in patients with multiple myeloma through a multifaceted mechanism of action. Direct on-tumor actions include complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and induction of apoptosis via crosslinking (1,12–14). Recently, RRMM patient samples were analyzed by flow cytometry for assessment of immune population count changes, in addition to evaluation of the functionality of CD38+ immune-cell populations, T-cell activation, and T-cell receptor clonality. The data revealed a previously unknown immune-modulatory mechanism of action of daratumumab that may contribute to prolonged and deep clinical responses (15). In that study, daratumumab was found to exert immune-modulatory effects via T-cell induction/expansion, T-cell activity enhancement, and reduction of immune-suppressive cell populations. These populations included CD38+ myeloid-derived suppressor cells, CD38+ regulatory T cells (Treg), and CD38+ regulatory B cells.

Further characterization of daratumumab’s immune-modulatory mechanism of action is desirable. Technical limitations of flow cytometry make broad surveys of the effects of daratumumab on additional subtypes of immune-cell populations unlikely with that technology alone (16,17). We therefore conducted a study using cytometry by time of flight (CyTOF®) to corroborate and build upon the findings of flow cytometry (16,18). Because CyTOF® enables the analysis of 35+ markers at the single-cell level without the need for compensation (18), it was used to deeply characterize the effects of daratumumab on immune cell subset composition and provide insights on functionality from a single-sample collection, moving well beyond the limitations of traditional flow cytometry. This approach was selected to increase robustness as an alternative to extrapolating conclusions from separate flow cytometry acquisitions. The objective of this study was to identify novel changes in immune-cell phenotypes that correlate with the efficacy and depth of response observed during treatment with daratumumab in patients with RRMM.

**METHODS**

**CyTOF® Sample Sources and Staining**

Full details on the study designs and patient populations included in GEN501 (5) and SIRIUS (6) studies have been previously published. GEN501 Part 2 (phase 2) and SIRIUS (phase 2) were single-arm studies of daratumumab monotherapy at 16 mg/kg in patients with heavily pre-treated RRMM. In SIRIUS, whole-blood (WB) samples were obtained from 32 patients at baseline and after 2 months on study. In GEN501, 5 patients provided WB and/or bone-marrow (BM) samples at baseline, after 2 months on study, and at the end of treatment. Samples were stained using the antibody panel in Supporting Information Table S1 and acquired on a CyTOF® C5 system. Clinical response data of the GEN501 Part 2 (5) and SIRIUS (6) studies were from patients who received daratumumab 16 mg/kg at the clinical cut-off date of January 9, 2015. Ethics committees or institutional review boards at each study site approved the study protocols and the study analysis plans (5,6). The studies were conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. All patients provided written informed consent.

**Data Pre-processing and Quality Control**

Following data acquisition, channel intensity was normalized using calibration beads. Data were gated using Cytobank® (www.cytobank.org; Cytobank, Inc., Santa Clara, CA, USA) and further processed using a set of custom scripts based on the flowCore package. Measured intensities for each channel were transformed using the arcsinh function with a cofactor of 5. Quality control assessment of 9 WB control samples from 9 different batches was performed using the earth mover’s distance algorithm (19) and marker enrichment modeling (20). These analyses revealed no evidence of technical sources of variation that needed batch correction (Fig. 1A,B).

**Identification of Immune-Cell Populations**

After identification of live single-cell events, similar cellular events were grouped together using the spanning-tree progression analysis of density normalized events (SPADE) algorithm (18,21). To ensure that every cell population was represented, the analysis included only samples in which at
least 10,000 events in the lymphocyte/monocyte population had been recorded.

**Differential Analysis of Immune-Cell Population Counts and Marker Intensities**

Sample group comparisons per marker were performed based on the sample annotation for different time points (before and after treatment) and response groups (responder and non-responder). For each sample, the mean marker intensity (MMI) was calculated for each cluster in the SPADE tree. A 2-sided 2-sample t-test allowing for unequal group variance was then performed to compare the group (time/response) MMI means. This analysis yielded raw P values for all cluster/marker combinations. In case of repeated observations over time for the same subject, response group means were calculated for the fold changes (MMI difference between two time points).

**Bin Analysis**

Changes in the distribution of signal intensity were quantified using the following procedure: for a given population and channel of interest, the centiles of the single-cell data were computed across all conditions and the values were used to define bins. Overlapping bins were merged when more than 1% of cells had similar signal intensity. The percentage of cells in each bin was then computed across conditions. To compare conditions, the fraction of cells in each bin for the condition of interest was compared with the total number of cells in the bin. The effect of treatment over time was visualized by plotting the cell fraction to the lower limit of intensity of each bin.

**Visualization**

Results of the statistical analysis of differences between conditions were visualized with a SPADE-blend tree, where each SPADE cluster is colored with a color gradient that reflects the dimensions of raw P values to fold changes computed between marker intensities or to differences in cell population fractions observed under different conditions. To visualize trends at the single-cell level, we used Radviz, a method in which cells are projected in two dimensions in a manner that preserves the original dimensions and enables rapid interpretation of changes within a population. Treatment effects on specific cell subsets were visualized using relevant channels representing different phenotypic and translational markers. Radviz shifts were used to guide manual gating and downstream statistical analysis. To explore the individual contributions of each channel and to assess the homogeneity of the response across a given cell population, we used the fan charts developed by the Bank of England.

**RESULTS**

**CD38 Expression and Modulation in Lymphocyte Populations and Natural Killer (NK)-Cell Reduction**

To further the understanding of the immune-modulatory activity of the CD38-targeting antibody daratumumab observed with flow cytometry, WB and BM samples...
from RRMM patients who received single-agent daratumumab in the SIRIUS (n = 32) and GEN501 (n = 5) studies were analyzed via CyTOF®. This platform allows for in-depth functional protein-level characterization at single-cell resolution and enables multidimensional, quantitative analysis of single-cell–level differences between patient subgroups or effects of therapeutics on cell populations and marker expression.

In alignment with earlier findings from BM samples profiled with flow cytometry (15), CyTOF® analysis showed that CD38 was expressed across various immune-cell subpopulations, including plasma cells, NK cells, monocytes, B cells, and T cells as shown in baseline BM samples of RRMM patients (Fig. 2). Also, confirming previously reported flow cytometry findings of peripheral blood mononuclear cells from daratumumab single agent–treated RRMM patients (24), CD38 marker intensity decreased over 2 months of treatment in WB samples from SIRIUS (from Cycle 1, Day 1 to Cycle 3, Day 1; Fig. 3A). The most prominent decrease was observed for NK cells, B cells, and naïve CD4+ T cells ($P^* = 0.0099$). Along with reduced CD38 expression, the NK-cell population was significantly depleted ($P^* = 0.0099$) in WB samples from SIRIUS (from Cycle 1, Day 1 to Cycle 3, Day 1; Fig. 3B, Supporting Information Fig. S1). NK cells were depleted in WB (data not shown) and BM samples from GEN501 but the NK-cell reductions were not statistically significant from Cycle 1, Day 1 to end of treatment (Fig. 3C, Supporting Information Fig. S1). Decreases in immune-suppressive cells, such as CD38+ Tregs, are described in greater detail below. Collectively, these findings align with flow cytometry observations performed in these clinical studies (25,26).

### Activated Phenotype of Remaining NK Cells

Interestingly, although NK cells were reduced upon daratumumab treatment, phenotypic changes were observed in the remaining cells of this immune population. Differential analysis and SPADE-blend tree visualization of WB samples from SIRIUS patients after 2 months of daratumumab treatment revealed significant decreases in CD45RA (NK, $P^* = 0.0198$; dim NK, $P^* = 0.0297$) and significant increases in CD69 and CD127 (NK, dim NK, bright NK, $P^* = 0.0198$; Supporting Information Fig. S2). In both SIRIUS and GEN501, a consistent trend toward decreased granzyme B and increased CD25, and increased CD137 and CD27 were observed. Similar trends of these proteins were observed in BM samples from patients in GEN501 (data not shown).

### Immune-Suppressive Populations and Basophils

To assess rare populations and their CD38+ subsets, WB samples from the SIRIUS trial were manually gated and analyzed. Beyond confirmation of the previously reported daratumumab-mediated depletion of immune-suppressive populations, like CD38+ Tregs (CD4+CD25+CD127−) (14) (Fig. 4A), our high-dimensional cytometry analysis enabled the first evaluation of basophils (CD45−CD123+HLA-DR−) under daratumumab treatment. Daratumumab reduced the percentage of CD38+ basophils after 2 months of monotherapy treatment, independent of response to treatment and the manifestation or grade of infusion-related reactions (IRRs) at first (Fig. 4B) or any infusion (data not shown). The baseline level of CD38+ basophils was also not associated with IRRs at first infusion.

To determine whether changes in CD38 signal intensity corresponded to a change in the composition of the cell population or to a change in gene expression, we implemented a new method, the bin analysis. In short, for each population the expression data of a given marker is first summarized by binning cells using the centiles of the distribution. Then, the number of cells per bin and per time point is computed and the number of cells post-treatment to the total number of cells in each bin is compared. The fraction of cells is constant at 50% if no change in gene expression distribution has occurred.

When changes in distribution of signal intensity were assessed with the bin analysis, the fraction of Tregs expressing low levels of CD38 was observed to have remained constant during the course of treatment (average of post-treatment to baseline change is 50%; Fig. 4C), while the fraction of Tregs expressing high levels of CD38 was decreased (average of post-treatment to baseline change is less than 50%; Fig. 4C). We interpret this change as shift in the Treg population, where cells expressing high levels of CD38 are depleted upon treatment with daratumumab. For basophils, however, the fraction

---

**Figure 2.** Hierarchy of CD38 expression across immune subtypes in bone-marrow samples of 3 RRMM GEN501 patients as assessed by CyTOF®. Exported patient-specific SPADE tree bubbles fcs files for corresponding immune-cell populations were concatenated and subsequently visualized using Cytobank® software. CD38 marker intensity in NK, monocyte, and B- and T-cell compartments. NK, natural killer; RRMM, relapsed/refractory multiple myeloma; NK, natural killer.
Figure 3. Pre- versus on- and post-daratumumab treatment samples revealed (A) CD38 expression changes in SIRIUS whole-blood samples across different immune cells and NK-cell depletion in (B) SIRIUS whole-blood and (C) GEN501 bone-marrow samples. Data is visualized using the SPADE-blend tree method, which involved the projection of the differential testing results (here, contrasting pre-versus on- and post-treatment sample data) as colored highlighting of the SPADE tree clusters to maximize exploration of the statistical analysis results, simultaneously, in the samples under investigation. SPADE, spanning-tree progression analysis of density-normalized events; NK, natural killer; C, cycle; D, day; MMI, mean marker intensity; ProInflamm Monos, pro-inflammatory monocytes; MDSC, myeloid-derived suppressor cell; PSMC, peripheral blood mononuclear cell; mDC, myeloid dendritic cell; pDC, plasmacytoid dendritic cell; NKT, natural killer T cell; Tcm, central memory T cell; Tem, effector memory T cell; Temra, effector memory RA+ T cell; Treg, regulatory T cell. Nodes are colored by decrease (cyan; green if significant [raw P value]) or increase (magenta; red if significant [raw P value]).
Figure 4. Depletion of the immune-suppressive populations (A) CD38+ Tregs and (B) CD38+ basophils in whole-blood samples from patients at baseline and after 2 months of daratumumab monotherapy treatment (SIRIUS). Analysis of changes in distribution of signal intensity shows a decrease in the fraction of Treg expressing high levels of CD38, suggesting a change in the Treg population (C). For basophils (D) a shift of cell fractions from high intensity to low intensity is observed, suggesting a change in CD38 expression. Treg, regulatory T-cell; IRR, infusion-related reaction; C, cycle; D, day; MMI, mean marker intensity. Lines indicate paired samples.
of cells expressing low levels of CD38 was greatly increased (average of post-treatment to baseline change is greater than 50%; Fig. 4D) while the fraction of cells expressing high levels of CD38 was decreased (average of post-treatment to baseline change is less than 50%; Fig. 4D), representing a decrease of CD38 expression in basophils upon treatment with daratumumab.

**T-Cell Phenotyping**

Distinct shifts in T-cell phenotypes are observed in WB after 2 months of daratumumab monotherapy. Of the CD4+ and CD8+ T cells that were both present at baseline (Fig. 5A, left panel, top figures, respectively), in responders, a distinct shift toward the CD8+ population was observed upon treatment in each study (lower right panels). Because shifts in Radviz plots correspond to either an increase in signal intensity in channels in the direction of the shift, or to a decrease in signal intensity on the opposite end of the circle, we used fan plots to identify the nature of the population change over treatment, using the asinh-transformed MMI values for selected channels (Fig. 5B). We confirmed the shift by computing the fraction of total T cells that are positive for Granzyme B, using a fixed threshold of 2 units (asinh-transformed MMI values) for all conditions. Interestingly, this shift to CD8+ T-cell prevalence was associated with an increase in granzyme B positivity, which is suggestive of increased killing capacity of the cytotoxic T cells (27). This observation was most pronounced in WB and BM of responders in both monotherapy studies.

Complementary manual gating performed on SIRIUS WB samples revealed changes in activation markers of CD8+ T cells. There was a significant increase ($P = 0.017$, Wilcoxon) in granzyme B production and trends for increased expression of CD69 and HLA-DR (Fig. 6A). Modest changes were observed in markers associated with exhaustion (Fig. 6B). Following daratumumab treatment, the median percentage of PD1+ CD8+ T cells decreased from baseline in responders (from 10.2% to 8.97%) but increased in non-responders (from 8.76% to 11.42%; Fig. 6B). However, neither change from baseline was statistically significant. Additionally, CD8+ T-cell changes were associated with minimal alterations of the exhaustion marker CTLA4 after 2 months of daratumumab treatment.

**DISCUSSION**

Daratumumab, a human monoclonal antibody that targets CD38, has demonstrated unprecedented clinical benefit and rapid, deep responses as monotherapy and in combination with standard-of-care regimens in patients with RRMM (5–10). Several studies have identified a variety of different mechanisms by which daratumumab exerts its anti-myeloma activity (1,12–15), which likely contributes to the significant treatment benefit associated with daratumumab in the RRMM setting (5–9).

In another recent study, we demonstrated that daratumumab’s mechanism of action includes immune-modulatory effects, in addition to the previously established direct, on-tumor effects (15). That study evaluated the impact of daratumumab on CD38+ immunosuppressive populations, T-cell proliferation and activation, and T-cell receptor clonality using WB and BM samples from patients who received daratumumab 16 mg/kg in the GEN501 study ($n = 42$) or the SIRIUS study ($n = 106$). Samples were analyzed using flow cytometry, functional assays, and T-cell receptor beta-chain repertoire sequencing. The study showed that daratumumab exerted immune-modulatory effects by expanding the T-cell population, while eliminating a population of highly immunosuppressive CD38+ Tregs, myeloid-derived suppressor cells, and regulatory B cells, thus stimulating T-cell effector functions (15).

We undertook the present study to complement the findings of Krejcik et al. (15), Nijhof et al. (24), and Casneuf et al. (26) assessing the effects of daratumumab on a more comprehensive profile of immune-cell populations and immune functional characteristics. Our objective was to identify changes in immune-cell profiles that correlated with efficacy and depth of response observed during treatment with daratumumab. Our primary analytical tool was CyTOF®, a next-generation mass cytometry platform (18). Compared with flow cytometry, CyTOF® greatly increases the number of parameters that can be measured simultaneously per cell by eliminating cell-dependent background signals and the need for mathematical correction of spectral overlap caused by fluorescence (18). We also introduce a novel tool for visualizing subgroup analysis results on SPADE trees by incorporating Radviz plots to better understand changes in response categories and with respect to time. Recent studies have started to incorporate the CyTOF® technology to examine immune responses to cancer therapies (28–30).

The results of our study confirm and build upon our previously reported flow cytometry findings (15). CD38 was found on plasma cells, NK cells, monocytes, B cells, and T cells in BM samples and peripheral blood mononuclear cell samples from RRMM patients. In line with Nijhof et al.’s findings in which CD38+ plasma cells were found to decrease over time (24), CyTOF® profiling shows decreased CD38 expression on many immune-cell subtypes in both WB and BM upon daratumumab monotherapy treatment (SIRIUS, GEN501). Manual gating of samples in the SIRIUS monotherapy study revealed decreased CD38+ Tregs (all patients) after 2 months of daratumumab monotherapy, which may contribute to the depth and durability of responses associated with daratumumab (5–9). Furthermore, CD38+ basophils, a type of granulocytic white blood cell that releases histamine as an inflammatory reaction during an immune response and contributes to anaphylactic reactions (31), were reduced independent of response. This decrease could be due solely to phenotypic changes after daratumumab engagement and may contribute to IRRs; however, their baseline level was found not to be correlated to the presence of IRRs at first infusion. To fully elucidate this element of immunological change, functional assays with basophils in the presence of daratumumab will need to be performed to properly assess the impact for treated patients.
Furthermore, in agreement with data we presented previously (25,26), our study has demonstrated that in addition to immune-suppressive cells, NK cells (CD45+CD3−CD56+/dim) are also reduced in patients treated with daratumumab. However, Casneuf et al. have shown that this reduction in NK cell number in daratumumab-treated patients does not negatively affect the therapeutic efficacy of the drug.

Figure 5. High-dimensional algorithm–based analysis result visualization of whole blood T-cell phenotypic changes in responders and non-responders from SIRIUS and GEN501 after 2 months of daratumumab monotherapy. (A) Radviz density projections of T cells from SIRIUS and GEN501 studies. (B) Fan plots and scatterplots of T-cell data from SIRIUS patients. Radviz plots of SPADE tree-defined T-cell populations reveal a shift to CD8 prevalence with granzyme B positivity in responders (red circles). Arrows on fan plots highlight the contribution of granzyme B to the phenotype of T cells at a given time point for patients. The analysis was based on whole-blood samples from 32 SIRIUS patients (17 non-responders; 15 responders) and 4 GEN501 patients (2 non-responders; 2 responders). SPADE, spanning-tree progression analysis of density-normalized events; WB, whole-blood; C, cycle; D, day; Inf, infusion.
impact the efficacy of daratumumab, nor does lack of NK cells increase the susceptibility of patients to infections (25,26). We made several novel observations when phenotypically characterizing the residual NK cells, including a significant decrease in CD45RA and increase in CD127 and CD69. While we observed trends for increased expression of CD27 in NK cells that persisted across WB and BM samples, and while there are conflicting hypotheses around the functional role of NK cells with this phenotype (32–35), the observed trends toward increased signal intensity of CD137 combined with increased levels of activation markers CD69 and CD25 may suggest any compromised cytolytic activity could be offset to allow for daratumumab-mediated antibody-dependent cellular cytotoxicity (32). Furthermore, Krzywinska et al. showed that in hematologic malignancies, NK cells with an immature profile are still able to show cytotoxic activity (36,37), and Wang et al. showed that post-daratumumab NK cells are more effective at eradicating myeloma cells (38). Recently, Feng et al. have demonstrated that isatuximab, another CD38-targeted monoclonal antibody, promotes NK-cell activity through interferon γ induction, as evidenced by CD107a upregulation. However, it remains unclear whether the authors also observed a decrease in the levels of NK cells following isatuximab treatment (39). While these in vitro findings require further validation, collectively they highlight the immune-modulatory role of CD38-targeted therapies. Subsequent studies will be required to explore the functional role of this unique population of NK cells in daratumumab-treated patients.

Of particular interest in our study are characteristics differentiating daratumumab-treated responders from non-responders. In an analysis of WB samples from SIRIUS and GEN501 patients, Radviz plots of SPADE tree-defined T-cell populations revealed a shift to CD8+ T-cell prevalence with granzyme B positivity following daratumumab treatment in responders. Manual gating of SIRIUS WB samples showed that there was a significant increase in granzyme B production among responders to daratumumab. This is important to note, given that recent studies have spoken to the varied functional status of both peripheral blood and BM T cells from multiple myeloma patients (40,41). Moreover, these findings align with work conducted by Chatterjee et al., which showed that inhibition of CD38 increased NAD+-dependent activity of Sirt1 and enhanced the anti-tumor effect of CD8+ T cells (42). Since the majority of our samples were from WB, we investigated this aspect of T-cell biology for markers associated with CD8+ T-cell exhaustion and showed that the median percentage of PD1+CD8+ T cells trended downward in responders but tended to increase in non-responders (both not significant). Additionally, daratumumab treatment minimally affected the exhaustion marker CTLA4. It is important to note that SIRIUS and GEN501 samples were assessed at the presumed initiation of daratumumab-mediated T-cell expansion (15). Therefore, most patient T cells will likely have had limited interaction with target cells and thus have a high intracellular granzyme B and low checkpoint receptor expression phenotype.

In summary, CyTOF® analysis of patient samples from studies of daratumumab therapy highlight the immune-modulatory mechanism of action of daratumumab. T-cell changes toward a cytolytic, granzyme B+ phenotype observed
in WB and BM and increased expression of the activation markers on NK cells, such as CD69, support an adaptive response in patients that may contribute to the depth of response observed in patients treated with daratumumab. Synonymous findings in WB and BM CyTOF® samples reinforce this platform’s ability to allow WB surrogacy for interpretation of the immune system in multiple myeloma, which is of high value to the field. These results build upon earlier findings and advocate further utility of CyTOF® and related methodologies to gain greater insights into the mechanism of action of daratumumab monotherapy and daratumumab in combination with other immune-modulatory agents.

ACKNOWLEDGMENTS

The authors would like to thank Berris van Kessel-Welmers for her support in sample operation and Tahamtan Ahmadi for oversight of these clinical studies. Editorial support was provided by Jason Jung, PhD, and Sima Patel, PhD, of MedErgy, and was funded by Janssen Global Services, LLC.

DISCLOSURE OF INTERESTS

H.C.A.III, F.S., K.V.d.B., T.S., J.B., Y.A., H.C., C.G., V.V., and T.C. are employees of Janssen. T.C., G.V., H.C., and A.K.S. report equity ownership in Johnson & Johnson. S.Z.U. received research funding from Onyx, Sanofi, Array BioPharma, Pharmacynics, Takeda, Celgene, and BMS; served as a consultant for Sanofi, Takeda, Celgene, and Amgen; served on advisory committees for Onyx, Sanofi, Celgene, Skyline, Millennium, and Janssen; and served on speakers bureaus for Takeda, Celgene, and Amgen. T.P. served on advisory committees for Janssen and Gennab and received research funding from Janssen. S.Z.U. served as a consultant for Millenium, Merck, BMS, Celgene, Novartis, Janssen, and Onyx. H.M.L. received research funding from Onyx and Gennab and served on advisory committees for Janssen and Gennab; and served on advisory committees for Janssen. T.M. received research funding from Celgene, Janssen, and Gennab, and served on advisory committees for Janssen. N.W.C.J.vdD. received research funding from and served on advisory committees for Janssen, Celgene, BMS, and Amgen. A.K.S. is a former employee of Janssen.

LITERATURE CITED

1. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DCH, Hamann J, Kuijpers TW, van Lier RAW. CD27 de
2. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of MM markers on NK cells, such as CD69, support an adaptive response in patients that may contribute to the depth of response observed in patients treated with daratumumab. Synonymous findings in WB and BM CyTOF® samples reinforce this platform’s ability to allow WB surrogacy for interpretation of the immune system in multiple myeloma, which is of high value to the field. These results build upon earlier findings and advocate further utility of CyTOF® and related methodologies to gain greater insights into the mechanism of action of daratumumab monotherapy and daratumumab in combination with other immune-modulatory agents.

ACKNOWLEDGMENTS

The authors would like to thank Berris van Kessel-Welmers for her support in sample operation and Tahamtan Ahmadi for oversight of these clinical studies. Editorial support was provided by Jason Jung, PhD, and Sima Patel, PhD, of MedErgy, and was funded by Janssen Global Services, LLC.

DISCLOSURE OF INTERESTS

H.C.A.III, F.S., K.V.d.B., T.S., J.B., Y.A., H.C., C.G., V.V., and T.C. are employees of Janssen. T.C., G.V., H.C., and A.K.S. report equity ownership in Johnson & Johnson. S.Z.U. received research funding from Onyx, Sanofi, Array BioPharma, Pharmacynics, Takeda, Celgene, and BMS; served as a consultant for Sanofi, Takeda, Celgene, and Amgen; served on advisory committees for Onyx, Sanofi, Celgene, Skyline, Millennium, and Janssen; and served on speakers bureaus for Takeda, Celgene, and Amgen. T.P. served on advisory committees for Janssen and Gennab and received research funding from Janssen. S.Z.U. served as a consultant for Millenium, Merck, BMS, Celgene, Novartis, Janssen, and Onyx. H.M.L. received research funding from Onyx and Gennab and served on advisory committees for Janssen and Gennab; and served on advisory committees for Janssen. T.M. received research funding from Celgene, Janssen, and Gennab, and served on advisory committees for Janssen. N.W.C.J.vdD. received research funding from and served on advisory committees for Janssen, Celgene, BMS, and Amgen. A.K.S. is a former employee of Janssen.

LITERATURE CITED

1. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DCH, Oomen LA, Peipp M, Valerius T, Slootstra JW, et al. Daratumumab, a novel thera-
2. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of MM markers on NK cells, such as CD69, support an adaptive response in patients that may contribute to the depth of response observed in patients treated with daratumumab. Synonymous findings in WB and BM CyTOF® samples reinforce this platform’s ability to allow WB surrogacy for interpretation of the immune system in multiple myeloma, which is of high value to the field. These results build upon earlier findings and advocate further utility of CyTOF® and related methodologies to gain greater insights into the mechanism of action of daratumumab monotherapy and daratumumab in combination with other immune-modulatory agents.

ACKNOWLEDGMENTS

The authors would like to thank Berris van Kessel-Welmers for her support in sample operation and Tahamtan Ahmadi for oversight of these clinical studies. Editorial support was provided by Jason Jung, PhD, and Sima Patel, PhD, of MedErgy, and was funded by Janssen Global Services, LLC.

DISCLOSURE OF INTERESTS

H.C.A.III, F.S., K.V.d.B., T.S., J.B., Y.A., H.C., C.G., V.V., and T.C. are employees of Janssen. T.C., G.V., H.C., and A.K.S. report equity ownership in Johnson & Johnson. S.Z.U. received research funding from Onyx, Sanofi, Array BioPharma, Pharmacynics, Takeda, Celgene, and BMS; served as a consultant for Sanofi, Takeda, Celgene, and Amgen; served on advisory committees for Onyx, Sanofi, Celgene, Skyline, Millennium, and Janssen; and served on speakers bureaus for Takeda, Celgene, and Amgen. T.P. served on advisory committees for Janssen and Gennab and received research funding from Janssen. S.L. served as a consultant for Sanofi, Takeda, Celgene, and Amgen. T.P. served on advisory committees for Janssen and Gennab and received research funding from Janssen. S.L. served as a consultant for Millenium, Merck, BMS, Celgene, Novartis, Janssen, and Onyx. H.M.L. received research funding from Onyx and Gennab and served on advisory committees for Janssen and Gennab; and served on advisory committees for Janssen. T.M. received research funding from Celgene, Janssen, and Gennab, and served on advisory committees for Janssen. N.W.C.J.vdD. received research funding from and served on advisory committees for Janssen, Celgene, BMS, and Amgen. A.K.S. is a former employee of Janssen.